Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials.

× No keyword cloud information.

4 in total

Review 1. Preventing disability in inflammatory bowel disease.

Authors: Patrick B Allen; Corinne Gower-Rousseau; Silvio Danese; Laurent Peyrin-Biroulet
Journal: Therap Adv Gastroenterol Date: 2017-10-16 Impact factor: 4.409

Review 2. Evolving therapeutic goals in Crohn's disease management.

Authors: Thomas Chateau; Laurent Peyrin-Biroulet
Journal: United European Gastroenterol J Date: 2019-11-04 Impact factor: 4.623

3. Protection by microRNA-7a-5p Antagomir Against Intestinal Mucosal Injury Related to the JNK Pathway in TNBS-Induced Experimental Colitis.

Authors: Bao Yin; Huang Tian-Chu; Xu Ling-Fen
Journal: Turk J Gastroenterol Date: 2021-05 Impact factor: 1.852

4. JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4⁺ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.

Authors: Rui Zhou; Ying Chang; Jing Liu; Min Chen; Hongling Wang; Meifang Huang; Shi Liu; Xiaobing Wang; Qiu Zhao
Journal: Front Immunol Date: 2017-07-04 Impact factor: 7.561

4 in total

The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials.

Review 1. Preventing disability in inflammatory bowel disease.

Review 2. Evolving therapeutic goals in Crohn's disease management.

3. Protection by microRNA-7a-5p Antagomir Against Intestinal Mucosal Injury Related to the JNK Pathway in TNBS-Induced Experimental Colitis.

4. JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.

4. JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4⁺ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease.